Search

1222498
1201004
1195994
393884
209802
ScimathUS
The South African Tuberculosis Vaccine Initiative will be offering a limited number of bursaries to cover the Registration Fees associated with the SciMathUS Program, a university preparation program which is offered by the Stellenbosch University...
Community Engagement
In March 2016 SATVI brought "Lienkie se Longe", a drama to raise awareness about TB, to the Worcester Easter Festival. The drama tells the story of Lienkie, whose lungs “talk with each other’ about their health and the health of Lienkie’s boyfriend...
Biomarker discovery offers hope for new TB vaccine development
A team of scientists from the University of Cape Town, Oxford University and the London School of Hygiene & Tropical Medicine have made a discovery that reveals how we can improve development of more effective vaccines against tuberculosis.
Community Engagement
In 2012 SATVI developed a drama production to promote awareness about TB vaccine clinical research, titled “Carina’s Choice” with learners from Worcester Secondary School as actors and UCT drama school students as mentors. A very successful roadshow...
Accredited UCT Research Centre
The South African Tuberculosis Vaccine Initiative (SATVI) is an accreditated Research Centre of the University of Cape Town.

News

Tuesday, 24 April 2018
11 April 2018 SATVI 2017 Annual Report Now available

The 2017 SATVI Annual Report is now available.

Publication Date:
Wednesday, April 11, 2018 - 13:00
Latest Research: Four-gene Pan-African Blood Signature Predicts Progression to Tuberculosis

Researchers at the South African Tuberculosis Vaccine Initiative have co-authored an article titled  "Four-gene Pan-African Blood Signature Predicts Progression to Tuberculosis" appearing in the American Journal of Respiratory and Critical Care Medicine.

 

Publication Date:
Monday, April 9, 2018 - 14:45
Postdoctoral Vacancy: TB Vaccine Trial Immunology

The South African Tuberculosis Vaccine Initiative invites applications for a Postdoctoral Fellowship to conduct research on the Immunology of TB vaccines. Closing date 15 May 2018.

Publication Date:
Friday, April 6, 2018 - 15:00
Latest Research: Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial

SATVI researchers have published an article titled: "Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial"  appearing in the latest Lancet Respiratory Medicine.

Publication Date:
Saturday, March 24, 2018 - 09:45

Pages